Radiographic progression in early rheumatoid arthritis patients following initial combination versus step-up treat-to-target therapy in daily clinical practice: results from the DREAM registry

Table 1 Patient characteristics

Characteristics	Strategy I (n = 128)	Strategy II (n = 128)	p
Female, sex n (%)	79 (61.7%)	79 (61.7%)	1.000
Age, mean ± SD years	59.1 ± 13.0	59,5 ± 12.8	0.809
DAS28 - ESR, mean ± SD	4.5 ± 1.1	4.8 ± 1.1	0.026
ESR (mm/h), median (IQR)	22.0 (14.0–41.0)	29.0^a (14.0–45.0)	0.195
CRP (mg/l), median (IQR)	10.0^b (5.0–22.0)	11.5 (4.3–24.8)	0.786
Anti-CCP positive, n (%)	74^c (58.3%)	77^c (60.2%)	0.701
RF positive, n (%)	62 (48.4%)	76 (59.4%)	0.114
Number of SJC, median (IQR)	6.0 (3.0–9.0)	5.0 (2.0–10.0)	0.235
Number of TJC, median (IQR)	3.0 (1.0–7.0)	4.0 (2.0–10.0)	0.025
HAQ-SDI, median (IQR)	1.2^d (0.9–1.6)	1.0^e (0.4–1.5)	0.003
VAS well-being, median (IQR)	50.0 (28.3–65.0)	51.0 (35.0–70.0)	0.290
VAS pain, median (IQR)	50.0^f (39.8–64.0)	62.0^g (49.0–75.0)	0.001
SF36-PCS, mean ± SD	38.1 ± 7.6^h	37.3 ± 9.2ⁱ	0.512
SF36-MCS, mean ± SD	40.7 ± 7.4^j	44.9 ± 11.9^k	0.003
BMI, kg/m², mean ± SD	26.5 ± 4.8^l	26.0 ± 4.1^m	0.388
Baseline SHS-score, median (IQR)	3.0 (1.0–7.0)ⁿ	2.0 (1.0–5.8)^o	0.119
Erosion, median (IQR)	0.0 (0.0–1.0)ⁿ	0.0 (0.0–1.0)^o	0.012
Joint space narrowing, median (IQR)	2.0 (0.0–5.0)ⁿ	1.0 (0.0–1.0)^o	0.586
Injection triamcinolone, n%	4 (3.1%)	67 (52.3%)	0.000

^a(n = 127), ^b(n = 121), ^c(n = 127), ^d(n = 102), ^e(n = 87), ^f(n = 122), ^g(72), ^h(n = 105), ⁱ(n = 86), ^j(n = 105), ^k(n = 86),^l(n = 126), ^m(n = 119), ⁿ(n = 126), ^o(n = 124)
DAS28 Disease Activity Score in 28 joints, ESR erythrocyte sedimentation rate, CRP C-reactive protein, TJC tender joint count, SJC swollen joint count, HAQ-SDI Health Assessment Questionnaire disability index (standard scoring), SF-36 Short-Form 36 health survey (version 2), PCS physical component summary, MCS mental component summary, BMI body mass index, RF rheumatoid factor, Anti-CCP anti-cyclic citrullinated peptide

ISSN: 2520-1026